{
    "nctId": "NCT05075512",
    "briefTitle": "The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer",
    "officialTitle": "A Prospective Study on Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With HR-positive and HER2-negative, Secondary Endocrine-resistant, Locally Advanced or Metastatic Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Neoplasm Female",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Progression-Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged 18 years or older female\uff1b\n* ECOG score 0-1;\n* Life expectancy is not less than 12 weeks;\n* Histology confirmed HR-positive and HER2-negative locally advanced or metastatic breast cancer;\n* Premenopausal women have taken effective ovarian function suppression methods, such as drug suppression or ovariectomy;\n* At least one objectively measurable breast cancer lesions according to RECIST 1.1 ;\n* No more than one systemic chemotherapy for metastatic disease;\n* Disease relapse within 12 months after at least 24 months endocrine adjuvant therapy, or disease progress after at least 6 months endocrine salvage therapy;\n* Normal function of main organs and bone marrow: Hemoglobin\u226590g/L; Neutrophil count (ANC)\u22651.5\u00d7109/L; Platelet count (PLT)\u226580\u00d7109/L; Total bilirubin\u22641.5\u00d7ULN (upper limit of normal); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 2.5\u00d7ULN (\u22645\u00d7ULN if has liver metastasis); Serum creatinine (Cr) \u22641.5\u00d7ULN or creatinine clearance \u226560mL/min (Cockcroft-Gault formula);\n* Sign the informed consent;\n\nExclusion Criteria:\n\n* Have received prior fulvestrant or anti-angiogenic drug treatment, or known to be allergic to any excipients in the study;\n* Visceral crisis;\n* Uncontrolled or high-burden CNS metastases;\n* Unable to swallow;\n* Abnormal coagulation function;\n* Tumor has invaded important blood vessels and may cause fatal bleeding;\n* Pleural effusion or pericardial effusion that requiring repeated drainage;\n* Hypertension that cannot be well controlled by a single antihypertensive drug;\n* Unstable angina, myocardial infarction within 6 months, serious arrhythmias;\n* The history of immunodeficiency, including HIV or other obtained or congenital immunodeficiency diseases, or a history of organ transplantation;\n* Poorly controlled diabetes;\n* Abnormal urine protein, and the 24-hour quantification suggests urine protein \u22651.0g;\n* Bleeding constitution or medical history\n* Unhealed wounds, ulcers or fractures;\n* Have arterial/venous thrombotic events within 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism;\n* In other clinical trials of anti-tumor drugs simultaneously;\n* Other concomitant disease or disability that endangers safety according to the judgment of investigator;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}